Palatin Technologies Inc.
ASE:PTN 11:12:22 AM EDT
Products, Regulatory
Palatin Technologies Announces Positive Results From Phase 2 Study Of Pl9643 In Patients With Dry Eye Disease
Published: 12/15/2020 13:46 GMT
Palatin Technologies Inc. (PTN) - Palatin Technologies Announces Positive Results From Its Phase 2 Study of Pl9643 in Patients With Dry Eye Disease.
Palatin Technologies Inc - Phase 2/3 Clinical Trial Currently Planned for Mid-2021.
Palatin Technologies Inc - There Were No Safety Signals Identified and Pl9643 Had Excellent Ocular Tolerability in Trial.
Palatin Technologies Inc - Statistically Significant Improvement in Moderate-to-severe Patients for Multiple Sign and Symptom Measures in Study.
Palatin Technologies Inc - Statistical Significance for Primary Endpoints Was Not Reached in Overall Enrolled Population in Study.
Palatin Technologies Inc - Phase 2/3 Clinical Trial Currently Planned for Mid-2021.
Palatin Technologies Inc - There Were No Safety Signals Identified and Pl9643 Had Excellent Ocular Tolerability in Trial.
Palatin Technologies Inc - Statistically Significant Improvement in Moderate-to-severe Patients for Multiple Sign and Symptom Measures in Study.
Palatin Technologies Inc - Statistical Significance for Primary Endpoints Was Not Reached in Overall Enrolled Population in Study.